FDA
-
-
-
-
-
-
-
Monopar begins rolling NDA submission for Wilson disease drug
-
-
-
-
-
-
-
Monopar presents Phase 3 Wilson disease data at EAN 2026
-
-
-
-
-
-
-
Leerink Partners on Monopar Therapeutics (MNPR): shares don't reflect 'magnitude of market opportunity'
-
-
-
-
-
-
-
Raymond James: 'Critical Week Coming Up for Monopar'
-
-
-
-
-
-
-
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
-
-
-
-
-
-
-
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
-
-
-
-
-
-
-
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
-
329,914 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

